Whalesbook
Marksans Pharma's UK subsidiary, Relonchem Limited, has received marketing authorization from the UK's MHRA for its Cetirizine Dihydrochloride 1 mg/ml oral solution, an anti-allergy medicine. This approval expands the company's allergy treatment portfolio and follows recent regulatory wins, including a US FDA approval for Loperamide Hydrochloride Tablets and another MHRA authorization for Mefenamic Acid tablets. Marksans Pharma's stock saw a slight increase following the announcement.